Frontiers in Gynecologic Oncology | Can Severe Endometriosis Significantly Increase the Risk of Ovarian Cancer?

Frontiers in Gynecologic Oncology | Can Severe Endometriosis Significantly Increase the Risk of Ovarian Cancer?

2024.09.09
A large population-based cohort study led by Dr. Mollie E. Barnard from the Huntsman Cancer Institute at the University of Utah has found that women with endometriosis have an overall higher risk of ovarian cancer, with the risk being significantly elevated in those with severe types of endometriosis. This study, published in the journal of the American Medical Association [1], suggests that these women may benefit from counseling on ovarian cancer risk and prevention, as well as potential ovarian cancer screening.
Lung Cancer Guidelines: ASCO Updates Stage III NSCLC Guidelines Based on LAURA Trial Data, Including Osimertinib

Lung Cancer Guidelines: ASCO Updates Stage III NSCLC Guidelines Based on LAURA Trial Data, Including Osimertinib

2024.09.09
The Phase 3 Non-Small Cell Lung Cancer (NSCLC) Treatment ASCO Guidelines has recently been updated, with the revisions based on the results of the Phase 3 LAURA trial. The findings were presented at the 2024 ASCO Annual Meeting and published simultaneously in the New England Journal of Medicine [1, 2]. The new guidelines include a recommendation to use the EGFR-TKI osimertinib in patients with unresectable Stage III NSCLC who have EGFR exon 19 deletions or exon 21 L858R mutations after definitive chemoradiotherapy (CRT).
Dr. Yue Lu: A Review and Update on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Dr. Yue Lu: A Review and Update on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

2024.09.08
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare malignancy of the hematopoietic system, is distinguished by its highly recognizable skin manifestations and complex pathophysiology, which continue to captivate the medical community's investigative spirit and challenge its resolve. Recently, Dr. Yue Lu from Lu Daopei Medical provided an in-depth analysis of BPDCN's origins, clinical presentation, diagnostic methods, and treatment advancements, shedding light on the cutting-edge developments in this field. The following article, based on his insights, has been prepared by Hematology Frontier for our readers.
Mutual Learning Between China and Germany丨International Perspectives, Leading the Frontier: The Academic Journey of Dr. Jürgen Wolf from the Universit

Mutual Learning Between China and Germany丨International Perspectives, Leading the Frontier: The Academic Journey of Dr. Jürgen Wolf from the Universit

2024.09.08
With an international perspective and a focus on leading-edge advancements, the Overseas Experts China Tour project welcomed a prominent figure in the field of lung cancer from August 5th to 10th, 2024—Dr. Jürgen Wolf, Director of the Centre for Integrated Oncology (CIO) at University Hospital of Cologne, Professor of Interdisciplinary Translational Oncology at the University of Cologne, and Head of the CIO Lung Cancer Program. During his five-day academic exchange tour in China, Professor Wolf visited Chengdu, Hangzhou, Changsha, and Qingdao, attracting lung cancer experts from across the country for discussions and exchanges. Throughout these academic activities, Professor Wolf not only shared the experiences of lung cancer diagnosis and treatment in Germany but also engaged in vigorous academic discussions with Chinese experts on the latest advancements and contentious topics in lung cancer treatment, sparking many brilliant ideas.